Essais liés8clinical trials
VilleSingaporelocalisation
PaysSingaporelocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT07047118

Ouvrir le site du centre

Essais cliniques associés

8
MoléculeIndication / populationPhaseNCTTitreStatut
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL Maladie coronarienne Phase 3 NCT05739383 A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. ACTIVE_NOT_RECRUITING
QCZ484 Hypertension Phase 2 NCT06857955 A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients ACTIVE_NOT_RECRUITING
ianalumab s.c. q4w Lupus Phase 3 NCT05126277 SIRIUS-LN — Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis ACTIVE_NOT_RECRUITING
68Ga-NNS309 Cancer Phase 1 NCT07261631 Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors RECRUITING
JSB462 Cancer Phase 2 NCT07047118 A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) ACTIVE_NOT_RECRUITING
rapcabtagene autoleucel Lupus Phase 2 NCT06581198 A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) ACTIVE_NOT_RECRUITING
Ianalumab Lupus Phase 3 NCT06711887 Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension) RECRUITING
Iptacopan (part 1) Lupus Phase 2 NCT05268289 Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V TERMINATED